Class action over Abbott's pricing of antiretroviral moves forwardBMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39257.587569.BE (Published 28 June 2007) Cite this as: BMJ 2007;334:1339
- Bob Roehr
- Washington, DC
A US judge has authorised a class action lawsuit against the drug company Abbott for its 400% hike in price, begun in late 2003, of the anti-HIV drug ritonavir (Norvir).
The lawsuit charges that the increase was a violation of US antitrust laws. It aims to roll back the increase and seeks compensation for everyone who has overpaid for the drug since the price increase.
Ritonavir had been developed as a protease inhibitor but did not work particularly well on its own. Over the course of using it with various combination treatments, clinicians observed a synergistic effect with other protease inhibitors. Ritonavir impeded the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial